阻断程序性死亡蛋白 1（PD-1）免疫抑制可增强嵌合抗原受体（CAR）T 细胞疗法。
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.
作者信息
John Liza B, Kershaw Michael H, Darcy Phillip K
机构信息
Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville, VIC Australia.
Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Department of Pathology; University of Melbourne; Parkville, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville, VIC Australia ; Department of Immunology; Monash University; Clayton, VIC Australia.
出版信息
Oncoimmunology. 2013 Oct 1;2(10):e26286. doi: 10.4161/onci.26286. Epub 2013 Oct 10.
The presence of an immunosuppressive microenvironment can limit the full potential of adoptive T cell immunotherapy. However, specific blockade of the PD-1 immunosuppressive pathway can significantly enhance the function of gene-modified T cells expressing a chimeric antigen receptor (CAR) leading to enhanced tumor eradication.
免疫抑制微环境的存在会限制过继性T细胞免疫疗法的全部潜力。然而，特异性阻断PD-1免疫抑制途径可显著增强表达嵌合抗原受体（CAR）的基因修饰T细胞的功能，从而增强肿瘤根除效果。
Zotero 插件